| 1 | Citrullinemia, classic | Enrichment | ASS1, SLC25A13 | 5.52 |
| 2 | Citrullinemia | Enrichment | ASS1, SLC25A13 | 5.52 |
| 3 | Citrin deficiency, adolescent or adult onset | Enrichment | ASS1, SLC25A13 | 5.05 |
| 4 | Pyloric stenosis, infantile hypertrophic, 1 | Enrichment | NOS1 | 3.43 |
| 5 | Argininosuccinic aciduria | Enrichment | ASL | 3.43 |
| 6 | Ornithine transcarbamylase deficiency, hyperammonemia due to | Enrichment | OTC | 3.35 |
| 7 | Pulmonary hypertension, neonatal | Enrichment | CPS1 | 3.35 |
| 8 | Disorder of ornithine metabolism | Enrichment | OTC | 3.35 |
| 9 | Spastic paraplegia 9a, autosomal dominant | Enrichment | ALDH18A1 | 3.35 |
| 10 | Cutis laxa, autosomal recessive, type iiia | Enrichment | ALDH18A1 | 3.35 |
| 11 | Spastic paraplegia 9b, autosomal recessive | Enrichment | ALDH18A1 | 3.35 |
| 12 | Cutis laxa, autosomal dominant 3 | Enrichment | ALDH18A1 | 3.35 |
| 13 | Autosomal recessive cutis laxa type iii | Enrichment | ALDH18A1 | 3.35 |
| 14 | Choroid disease | Enrichment | OAT | 3.35 |
| 15 | Autosomal dominant complex spastic paraplegia type 9b | Enrichment | ALDH18A1 | 3.35 |
| 16 | Myoglobinuria, recurrent | Enrichment | MT-CO1 | 3.29 |
| 17 | Myopathy, sarcoplasmic body | Enrichment | MB | 3.29 |
| 18 | Hereditary paraganglioma-pheochromocytoma syndromes | Enrichment | FH, MDH2 | 3.21 |
| 19 | Hereditary breast ovarian cancer syndrome | Enrichment | CPS1, SLC25A15 | 3.15 |
| 20 | Alzheimer disease 2 | Enrichment | NOS3 | 3.13 |
| 21 | Pre-eclampsia | Enrichment | NOS3 | 3.13 |
| 22 | Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome | Enrichment | SLC25A15 | 3.13 |
| 23 | Developmental and epileptic encephalopathy 1 | Enrichment | MDH2, SLC25A12 | 3.06 |
| 24 | Carbamoyl phosphate synthetase i deficiency, hyperammonemia due to | Enrichment | CPS1 | 3.05 |
| 25 | Argininemia | Enrichment | ARG1 | 3.05 |
| 26 | Hyperprolinemia, type i | Enrichment | PRODH | 3.05 |
| 27 | Schizophrenia 4 | Enrichment | PRODH | 3.05 |
| 28 | Spastic paraplegia 5a, autosomal recessive | Enrichment | ALDH18A1 | 3.05 |
| 29 | Xanthinuria, type i | Enrichment | XDH | 2.99 |
| 30 | Methemoglobinemia, alpha type | Enrichment | HBA1 | 2.99 |
| 31 | Gyrate atrophy of choroid and retina | Enrichment | OAT | 2.88 |
| 32 | Autosomal dominant cutis laxa | Enrichment | ALDH18A1 | 2.88 |
| 33 | Glycogen storage disease ia | Enrichment | ASS1 | 2.83 |
| 34 | Idiopathic achalasia | Enrichment | NOS1 | 2.83 |
| 35 | N-acetylglutamate synthase deficiency | Enrichment | NAGS | 2.83 |
| 36 | Stroke, ischemic | Enrichment | NOS3 | 2.83 |
| 37 | Keratoderma, palmoplantar, with deafness | Enrichment | MT-CO1 | 2.81 |
| 38 | Alpha thalassemia-intellectual disability syndrome type 1 | Enrichment | HBA1 | 2.81 |
| 39 | Xanthinuria, type ii | Enrichment | XDH | 2.81 |
| 40 | Myelodysplastic syndrome with ring sideroblasts | Enrichment | MT-CO1 | 2.81 |
| 41 | Cutis laxa, autosomal recessive, type iiib | Enrichment | PYCR1 | 2.81 |
| 42 | Bachmann-bupp syndrome | Enrichment | ODC1 | 2.81 |
| 43 | Sarcosinemia | Enrichment | SARDH | 2.81 |
| 44 | Intellectual developmental disorder, x-linked, syndromic, snyder-robinson type | Enrichment | SMS | 2.81 |
| 45 | Hyperinsulinemic hypoglycemia, familial, 6 | Enrichment | GLUD1 | 2.81 |
| 46 | Cutis laxa, autosomal recessive, type iib | Enrichment | PYCR1 | 2.81 |
| 47 | Syndromic x-linked intellectual disability snyder type | Enrichment | SMS | 2.81 |
| 48 | Hereditary leiomyomatosis and renal cell cancer | Enrichment | FH | 2.75 |
| 49 | Fumarase deficiency | Enrichment | FH | 2.75 |
| 50 | Developmental and epileptic encephalopathy 39 with leukodystrophy | Enrichment | SLC25A12 | 2.75 |
| 51 | Leiomyoma cutis | Enrichment | FH | 2.75 |
| 52 | Aspartate aminotransferase, serum level of, quantitative trait locus 1 | Enrichment | GOT1 | 2.75 |
| 53 | Lactate dehydrogenase b deficiency | Enrichment | LDHB | 2.75 |
| 54 | Developmental and epileptic encephalopathy 51 | Enrichment | MDH2 | 2.75 |
| 55 | Fumarate hydratase deficiency | Enrichment | FH | 2.75 |
| 56 | Developmental and epileptic encephalopathy 39 | Enrichment | SLC25A12 | 2.75 |
| 57 | Citrullinemia type ii | Enrichment | SLC25A13 | 2.75 |
| 58 | Erythrocytosis, familial, 7 | Enrichment | HBA1 | 2.69 |
| 59 | Hemoglobin h disease | Enrichment | HBA1 | 2.69 |
| 60 | Hereditary recurrent myoglobinuria | Enrichment | MT-CO1 | 2.69 |
| 61 | Alzheimer disease, familial, 1 | Enrichment | NOS3 | 2.60 |
| 62 | Hypertension, essential | Enrichment | NOS3 | 2.60 |
| 63 | Pain disorder | Enrichment | OAT | 2.58 |
| 64 | West syndrome | Enrichment | MDH2, SLC25A12 | 2.57 |
| 65 | Deafness, nonsyndromic sensorineural, mitochondrial | Enrichment | MT-CO1 | 2.51 |
| 66 | Methemoglobinemia, beta type | Enrichment | HBA1 | 2.51 |
| 67 | Autosomal dominant secondary polycythemia | Enrichment | HBA1 | 2.51 |
| 68 | Fanconi renotubular syndrome 1 | Enrichment | GATM | 2.51 |
| 69 | Cerebral creatine deficiency syndrome 2 | Enrichment | GAMT | 2.51 |
| 70 | Cerebral creatine deficiency syndrome | Enrichment | GAMT | 2.51 |
| 71 | Cerebral creatine deficiency syndrome 3 | Enrichment | GATM | 2.51 |
| 72 | Creatine deficiency disorders | Enrichment | GAMT | 2.51 |
| 73 | Malaria | Enrichment | NOS2 | 2.47 |
| 74 | Leiomyoma, uterine | Enrichment | FH | 2.45 |
| 75 | Hyperprolinemia, type ii | Enrichment | ALDH4A1 | 2.45 |
| 76 | Citrin deficiency, neonatal or infantile onset | Enrichment | SLC25A13 | 2.45 |
| 77 | Developmental and epileptic encephalopathy 82 | Enrichment | GOT2 | 2.45 |
| 78 | Developmental and epileptic encephalopathy 88 | Enrichment | MDH1 | 2.45 |
| 79 | Spinocerebellar ataxia 45 | Enrichment | FH | 2.45 |
| 80 | Myasthenic syndrome, congenital, 4c, associated with acetylcholine receptor deficiency | Enrichment | ASL | 2.43 |
| 81 | Heinz body anemias | Enrichment | HBA1 | 2.38 |
| 82 | Heinz body anemia | Enrichment | HBA1 | 2.38 |
| 83 | Mitochondrial myopathy, infantile, transient | Enrichment | MT-CO1 | 2.33 |
| 84 | Alpha-thalassemia | Enrichment | HBA1 | 2.33 |
| 85 | Geroderma osteodysplasticum | Enrichment | PYCR1 | 2.33 |
| 86 | Fanconi syndrome | Enrichment | GATM | 2.33 |
| 87 | Familial colorectal cancer | Enrichment | MT-CO1 | 2.29 |
| 88 | Mitochondrial myopathy with reversible cytochrome c oxidase deficiency | Enrichment | MT-CO1 | 2.29 |
| 89 | Rare mitochondrial non-syndromic sensorineural deafness | Enrichment | MT-CO1 | 2.29 |
| 90 | Aminoacylase 1 deficiency | Enrichment | ACY1 | 2.21 |
| 91 | Primary fanconi renotubular syndrome | Enrichment | GATM | 2.21 |
| 92 | Protein-deficiency anemia | Enrichment | HBA1 | 2.17 |
| 93 | Cox deficiency, benign infantile mitochondrial myopathy | Enrichment | MT-CO1 | 2.14 |
| 94 | Smith-magenis syndrome | Enrichment | SMS | 2.11 |
| 95 | Primary ovarian insufficiency | Enrichment | NOS3 | 2.06 |
| 96 | Hyperinsulinemic hypoglycemia, familial, 1 | Enrichment | GLUD1 | 2.03 |
| 97 | Nonsyndromic genetic hyperinsulinism | Enrichment | GLUD1 | 2.03 |
| 98 | Mitochondrial complex iv deficiency, nuclear type 1 | Enrichment | MT-CO1 | 1.95 |
| 99 | Congenital nervous system abnormality | Enrichment | ALDH18A1, GAMT | 1.94 |
| 100 | Nervous system disease | Enrichment | ALDH18A1, GAMT | 1.94 |
| 101 | Tetralogy of fallot | Enrichment | MT-CO1 | 1.87 |
| 102 | Hydrops fetalis, nonimmune | Enrichment | HBA1 | 1.87 |
| 103 | Mitochondrial complex v deficiency, mitochondrial type 1 | Enrichment | MT-CO1 | 1.87 |
| 104 | Neuropathy, ataxia, and retinitis pigmentosa | Enrichment | MT-CO1 | 1.87 |
| 105 | Striatonigral degeneration, infantile, mitochondrial | Enrichment | MT-CO1 | 1.87 |
| 106 | Camptodactyly of fingers | Enrichment | MT-CO1 | 1.87 |
| 107 | Cutis laxa | Enrichment | PYCR1 | 1.73 |
| 108 | Hereditary spastic paraplegia | Enrichment | ALDH18A1 | 1.73 |
| 109 | Leber hereditary optic neuropathy, modifier of | Enrichment | MT-CO1 | 1.72 |
| 110 | Optic atrophy plus syndrome | Enrichment | OAT | 1.71 |
| 111 | Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes | Enrichment | MT-CO1 | 1.71 |
| 112 | Hypertelorism | Enrichment | MT-CO1 | 1.58 |
| 113 | Parkinson's disease | Enrichment | GAMT | 1.54 |
| 114 | Leigh syndrome, nuclear | Enrichment | MT-CO1 | 1.45 |
| 115 | Parkinson disease, late-onset | Enrichment | GAMT | 1.44 |
| 116 | Hepatocellular carcinoma | Enrichment | FH | 1.42 |
| 117 | Leigh disease | Enrichment | MT-CO1 | 1.41 |
| 118 | Colorectal cancer | Enrichment | MT-CO1 | 1.36 |
| 119 | Mitochondrial disease | Enrichment | MT-CO1 | 1.36 |
| 120 | Leber plus disease | Enrichment | MT-CO1 | 1.32 |
| 121 | Connective tissue disease | Enrichment | PYCR1 | 1.31 |
| 122 | Developmental and epileptic encephalopathy | Enrichment | GOT2 | 1.21 |
| 123 | Retinitis pigmentosa | Enrichment | MT-CO1 | 0.98 |
| 124 | Hereditary retinal dystrophy | Enrichment | OAT | 0.91 |
| 125 | Fundus dystrophy | Enrichment | OAT | 0.91 |
| 126 | Ovarian cancer | Enrichment | FH | 0.78 |
| 127 | Inherited cancer-predisposing syndrome | Enrichment | FH | 0.68 |